Volume 18, Issue 9, Pages (September 2011)

Slides:



Advertisements
Similar presentations
Volume 13, Pages (November 2016)
Advertisements

Peptide reactivity between multiple sclerosis (MS) CSF IgG and recombinant antibodies generated from clonally expanded plasma cells in MS CSF  Xiaoli.
Pratistha Ranjitkar, Amanda M. Brock, Dustin J. Maly 
Michael T. Jacobsen, Michael Fairhead, Per Fogelstrand, Mark Howarth 
Disruption of Protein-Membrane Binding and Identification of Small-Molecule Inhibitors of Coagulation Factor VIII  P.Clint Spiegel, Shari M. Kaiser, Julian.
The Small-Molecule Iron Transport Inhibitor Ferristatin/NSC Promotes Degradation of the Transferrin Receptor  Lior Horonchik, Marianne Wessling-Resnick 
Volume 21, Issue 12, Pages (December 2014)
Arvin C. Dar, Michael S. Lopez, Kevan M. Shokat  Chemistry & Biology 
Volume 22, Issue 7, Pages (July 2015)
Volume 90, Issue 7, Pages (April 2006)
Generation of a Large Number of Connective Tissue Type Mast Cells by Culture of Murine Fetal Skin Cells  Nobuo Yamada, Hironori Matsushima, Yutaka Tagaya,
Volume 21, Issue 12, Pages (December 2014)
Volume 19, Issue 8, Pages (August 2012)
Volume 17, Issue 11, Pages (November 2010)
Shape Shifting Leads to Small-Molecule Allosteric Drug Discovery
Volume 14, Issue 11, Pages (November 2007)
Highly Efficient Self-Replicating RNA Enzymes
Volume 19, Issue 7, Pages (July 2012)
Volume 18, Issue 6, Pages (December 2015)
Volume 12, Issue 1, Pages (January 2005)
Inhibition of FcεRI-dependent mediator release and calcium flux from human mast cells by sialic acid–binding immunoglobulin-like lectin 8 engagement 
Volume 14, Issue 1, Pages (January 2007)
Discovery of Peptoid Ligands for Anti-Aquaporin 4 Antibodies
Volume 19, Issue 4, Pages (April 2012)
Volume 20, Issue 6, Pages (June 2013)
Structure-Guided Design of Fluorescent S-Adenosylmethionine Analogs for a High- Throughput Screen to Target SAM-I Riboswitch RNAs  Scott F. Hickey, Ming C.
Jennifer J Kohler, Carolyn R Bertozzi  Chemistry & Biology 
Volume 18, Issue 9, Pages (September 2011)
Potent and Selective Peptidyl Boronic Acid Inhibitors of the Serine Protease Prostate- Specific Antigen  Aaron M. LeBeau, Pratap Singh, John T. Isaacs,
Crystal Structure of the Human High-Affinity IgE Receptor
Beena Krishnan, Lila M. Gierasch  Chemistry & Biology 
PqsE of Pseudomonas aeruginosa Acts as Pathway-Specific Thioesterase in the Biosynthesis of Alkylquinolone Signaling Molecules  Steffen Lorenz Drees,
Volume 20, Issue 2, Pages (February 2013)
Volume 18, Issue 8, Pages (August 2010)
Volume 86, Issue 6, Pages (June 2004)
Michael T. Jacobsen, Michael Fairhead, Per Fogelstrand, Mark Howarth 
Tom E. Williams, Shanmugam Nagarajan, Periasamy Selvaraj, Cheng Zhu 
Volume 10, Issue 3, Pages (September 2011)
Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors
Volume 14, Issue 10, Pages (October 2007)
Volume 20, Issue 1, Pages (January 2013)
Kevin M. Marks, Michael Rosinov, Garry P. Nolan  Chemistry & Biology 
Volume 12, Issue 7, Pages (July 2004)
Volume 19, Issue 9, Pages (September 2012)
Array-Based Functional Screening of Heparin Glycans
Volume 90, Issue 7, Pages (April 2006)
An Electrophoretic Mobility Shift Assay Identifies a Mechanistically Unique Inhibitor of Protein Sumoylation  Yeong Sang Kim, Katelyn Nagy, Samantha Keyser,
Volume 17, Issue 11, Pages (November 2010)
Volume 17, Issue 11, Pages (November 2010)
Conformation-Selective ATP-Competitive Inhibitors Control Regulatory Interactions and Noncatalytic Functions of Mitogen-Activated Protein Kinases  Sanjay B.
Volume 17, Issue 10, Pages (October 2010)
UA62784 Is a Cytotoxic Inhibitor of Microtubules, not CENP-E
Lecture 14 Antibody-Antigen Reactions
Pratistha Ranjitkar, Amanda M. Brock, Dustin J. Maly 
Oktay Kirak, MD, Gert Riethmüller, MD 
Volume 8, Issue 4, Pages (April 1998)
Volume 21, Issue 9, Pages (September 2014)
Volume 19, Issue 8, Pages (August 2012)
Arvin C. Dar, Michael S. Lopez, Kevan M. Shokat  Chemistry & Biology 
Volume 12, Issue 9, Pages (September 2005)
Stefan T Arold, Maria K Hoellerer, Martin E.M Noble  Structure 
Ali Sadeghi-Khomami, Michael D. Lumsden, David L. Jakeman 
Phillip D. Holler, David M. Kranz  Immunity 
Increased TCR Avidity after T Cell Activation
Volume 16, Issue 9, Pages (September 2009)
Volume 8, Issue 2, Pages (February 1998)
Small, Mobile FcɛRI Receptor Aggregates Are Signaling Competent
Volume 17, Issue 8, Pages (August 2010)
Fine Details of IGF-1R Activation, Inhibition, and Asymmetry Determined by Associated Hydrogen /Deuterium-Exchange and Peptide Mass Mapping  Damian Houde,
Volume 21, Issue 9, Pages (September 2014)
Presentation transcript:

Volume 18, Issue 9, Pages 1179-1188 (September 2011) Design of a Heterobivalent Ligand to Inhibit IgE Clustering on Mast Cells  Michael W. Handlogten, Tanyel Kiziltepe, Demetri T. Moustakas, Başar Bilgiçer  Chemistry & Biology  Volume 18, Issue 9, Pages 1179-1188 (September 2011) DOI: 10.1016/j.chembiol.2011.06.012 Copyright © 2011 Elsevier Ltd Terms and Conditions

Chemistry & Biology 2011 18, 1179-1188DOI: (10. 1016/j. chembiol. 2011 Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 1 Inhibition of Mast Cell Degranulation Using Heterobivalent Ligands (A) Degranulation occurs when a multivalent antigen binds to multiple IgE antibodies on the surface of mast cells causing cross-linking of the IgE receptor, FcεRI, initiating a signaling cascade that results in the release of histamine and other inflammatory and cytotoxic molecules. (B) Heterobivalent ligands were engineered to simultaneously bind to the antigen binding region and the nucleotide binding pocket on the Fab domains of an IgE. Due to the enhanced avidity of the heterobivalent ligand, it inhibits the binding of the allergen to the surface bound IgE thus preventing degranulation. Chemistry & Biology 2011 18, 1179-1188DOI: (10.1016/j.chembiol.2011.06.012) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 2 Location of the Conserved Nucleotide Binding Site in Antibodies (A) Representative crystal structure of an IgG antibody (PDB 1IGY). Enlarged view of the Fab region of an immunoglobulin with the antigen and nucleotide binding sites labeled. (B) Backbone alignment of nine IgE antibody structures with the residues that make up the nucleotide binding pocket shown. PDB numbers for the IgE crystal structures: 2VXQ, 2R56, 1OAQ, 1OAR, 1OAU, 1OAX, 1OAY, 1OAZ, and 1OCW. (C) Backbone alignment of 18 IgG, IgM, and IgE antibody structures with the residues of the nucleotide binding pocket shown. The invariability of the side chain configurations demonstrate that the nucleotide binding pocket is conserved through these various isotypes of antibodies. PDB numbers for the overlaid crystal structures are 1DN0, 1DQL, 2VXQ, 2R56, 1AE6, 1BBD, 1DBB, 1F58, 1GGB, 1HIM, 1IGF, 1IKF, 1MAM, 1MRD, 1NCD, 1Q9W, 1UZ8, and 2IFF. Chemistry & Biology 2011 18, 1179-1188DOI: (10.1016/j.chembiol.2011.06.012) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 3 HBL2 Binds to IgEDNP with 124-Fold Affinity over ML1 (A) Representative binding curves for HBL2 (■), monovalent NF (ML1: ○), and monovalent IBA (ML2: ▾) binding to IgEDNP. Binding was observed by monitoring fluorescence quenching of tryptophan as described in the Experimental Procedures section. Values for the various molecules: KdHBL2 = 0.33 ± 0.07 μM, KdML1 = 41 ± 3 μM, and KdML2 = 4.5 ± 0.6 μM. In a separate experiment EDANS did not bind to IgEDNP over this concentration range (Figure S1). (B) Effective inhibitory concentrations of monovalent NF (ML1: ○) and HBL2 (■) were compared in an ELISA assay. BSA conjugated nitrofuran was adsorbed onto the surface of a 96-well plate and increasing concentrations of either HBL2 or ML1 were incubated with IgEDNP antibody prior to the addition to the wells. Inhibition was measured by monitoring the activity of HRP conjugated to a secondary antibody (anti-mouse IgE from goat). IC50HBL2 = 0.45 ± 0.05 μM and the IC50ML1 = 55 ± 5 μM. The error bars are standard deviations from at least triplicate measurements. Chemistry & Biology 2011 18, 1179-1188DOI: (10.1016/j.chembiol.2011.06.012) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 4 HBL2 Successfully Inhibits Mast Cell Degranulation (A) Dose response of RBL mast cell degranulation in response to increasing concentrations of NF-BSA. Triton X (1%) was used to normalize the percent degranulation in response to NF-BSA. (B) Inhibitory potentials of monovalent NF (ML1: ○) and HBL2 (■) were compared in a cellular assay by measuring the activity of β-hexoamidase, an enzyme released during RBL degranulation (Blank and Rivera, 2006). Cells were first treated with saturating concentrations of IgEDNP, and were then activated by NF-BSA. The IC50 of HBL2 was determined to be 15 ± 2 μM and no inhibition was observed over this range with ML1. In separate experiments IBA did not inhibit degranulation (Figure S2) and the necessity of the antigen binding moiety was demonstrated (Figure S3). The error bars are standard deviations from at least triplicate measurements. Chemistry & Biology 2011 18, 1179-1188DOI: (10.1016/j.chembiol.2011.06.012) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 5 Bivalent Binding Enhances Ligand Avidity Reaction equilibria for the binding of heterobivalent ligands to IgEDNP. The KdObs are the reported binding constants for the heterobivalent ligands listed in Table 1. KdAnt is the dissociation constant of monovalent hapten (ML1), and KdNuc is the dissociation constant of monovalent nucleotide analog (ML2). JAnt and JNuc are the unitless intramolecular binding constants for antigen and nucleotide analog respectively. We calculated the values for these constants to be JNuc = 0.008 and JAnt = 0.073 for HBL2 binding to IgEDNP. Chemistry & Biology 2011 18, 1179-1188DOI: (10.1016/j.chembiol.2011.06.012) Copyright © 2011 Elsevier Ltd Terms and Conditions